UNIVERSITY OF ALBERTA | MAZANKOWSKI ALBERTA HEART INSTITUTE

21st ANNUAL CARDIOLOGY UPDATE

Saturday, May 7, 2022

wELCOME

What is Cardiology Update?

This one-day live virtual program will provide participants with practical and up-to-date information on the management of cardiac patients in the primary care setting.

This year's program will include a combination of presentations and opportunities for participants and faculty to interact.


Who should attend?

  • Urban and Rural Primary Care Physicians

  • Internists / ER Physicians

  • Nursing Student, Nurses and Nurse Practitioners

  • Allied Health Professionals

  • Medical Students, Fellows and Residents

  • Pharmacy Students / Pharmacists

What are the course objectives?

Completion of this program, participants will be able to:

  • Describe the evidence behind new therapy recommendations, including the REDUCE-IT trial, which showed a reduction in CV outcomes with icosapent ethyl in patients with elevated triglycerides.

  • Recognize myocarditis as a possible consequence of COVID-19 infection.

  • Describe the results and implications of the EMPEROR-PRESERVED trial, which evaluated the effects of empagliflozin in HFpEF patients with and without diabetes.

  • Review the history of clinical trials regarding rate vs. rhythm control in non-valvular atrial fibrillation.

  • List sex differences between men and women in the presentation of chest pain.

  • Explore the CV and Renal outcomes of newer medications, including SGLT-2 inhibitors, finerenone, and GLP-1 agonists.

2022 Program

07:55 - 08:00

Welcome


08:00 - 09:40

Sessions 1 & 2

09:40 - 09:45

Break


09:45 - 11:25

Sessions 3 & 4

11:25 - 11:30

Break


11:30- 13:10

Sessions 5 & 6

13:10 - 13:15

Closing Remarks

2022 speakers & presentations

Session 1

08:00 - 08:40 | Q&A 08:40 - 08:50

Out with the Old and In with the New!

Highlights from the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines

Glen Pearson, PharmD


Learning Objectives (1) Describe the evidence behind new therapy recommendations, including the REDUCE-IT trial, which showed a reduction in CV outcomes with icosapent ethyl in patients with elevated triglycerides. (2) Explain the role of new lipid parameters (Lp(a), non-HDL-C, and ApoB) and the new lipid thresholds for therapy intensification. (3) Review other practice-changing updates from the guidelines, including screening in all women with pregnancy complications and the role coronary artery calcium score as part of patient assessment.

Session 2

08:50 - 09:30 | Q&A 09:30 - 09:40

COVID-19 Myocarditis, Vaccine Related Myocarditis and Cardiac Implications of Post-COVID Syndrome | What you Need to Know

Ian Paterson, MD


Learning Objectives (1) Recognize myocarditis as a possible consequence of COVID-19 infection. (2) Review the diagnosis, workup, and management of patients with COVID-19 myocarditis.

Session 3

09:45 - 10:25 | Q&A 10:25 - 10:35

The Good, the Bad, and the Ugly

Everything You Need to Know About the Management of Heart Failure with Preserved Ejection Fraction (HFpEF).

Sheri Koshman, PharmD


Learning Objectives (1) Describe the results and implications of the EMPEROR-PRESERVED trial, which evaluated the effects of empagliflozin in HFpEF patients with and without diabetes. (2) Explain the evidence and role of other therapies investigated in HFpEF and how it applies to the management of HFpEF patients.

Session 4

10:35 - 11:15| Q&A 11:15- 11:25

Rate vs Rhythm Control in Atrial Fibrillation

What is the New Consensus?

Haran Yogasundaram, MD


Learning Objectives (1) Review the history of clinical trials regarding rate vs. rhythm control in non-valvular atrial fibrillation. (2) Describe the latest Canadian guidelines on atrial fibrillation and changes from the previous guidelines. (3) Outline ongoing and future trials that may inform rate vs. rhythm control in future practice.

Session 5

11:30 - 12:10 | Q&A 12:10 - 12:20

Approach to Assessing and Managing Chest Pain in Women

Michelle Graham, MD


Learning Objectives (1) List sex differences between men and women in the presentation of chest pain. (2) Describe the care gap between men and women for various cardiovascular conditions. (3) Outline differences in the management of men and women for various cardiovascular conditions. (4) Describe strategies to mitigate systemic biases such as ensuring adequate representation in clinical trial.

Session 6

12:20 - 13:00 | Q&A 13:00 - 13:10

To Kill Two Birds with One Stone? Therapies That Can Offer Both Cardiovascular and Renal Protection

Alexandra Saunders, MD


Learning Objectives (1) Explore the CV and Renal outcomes of newer medications, including SGLT-2 inhibitors, finerenone, and GLP-1 agonists. (2) Define the patient population that would benefit from these newer therapies and how it can be applied to practice.

2022 Registration & Professional Development

Registration Sold Out

The 2022 program registration will only be available between April 1-25, 2022.


Note: All successfully registered participants will receive an email confirmation on May 2 with session links. You must be able to join/dial-in within Alberta to attend any/all sessions. Please download Zoom if you have not already done so via https://zoom.us/download.

Professional Development

All attendees will receive a Certificate of Attendance confirming hours.


Note: Certificates will be emailed to all registered participants by May 10, 2022.

The Canadian Council on Continuing Education in Pharmacy has accredited this program for 5.0 CEUs.

2022 evaluationS

Speaker Evaluation Closed

Program Evaluation Closed

2022 sponsors

Gold Level Sponsors
Bronze Level Sponsors
Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Approximately 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada. Learn more at www.boehringer-ingelheim.ca. Reviewed by PAAB
Download the Jardiance Dose CardDownload the Jardiance Patient BrochureDownload the Jardiance for HCP Brochure

2022 RESOURCES

2022 Steering committee

Cardiology Update is mandated to develop a high quality program and to help extend the learning experience by the following 2022 volunteer committee members.

Kevin Bainey, MD

Program Chair

Bio | Kevin.Bainey@ahs.ca

Hazal Babadagli, PharmD

Member Representing Pharmacy

Bio | Hazal.Babadagli@ahs.ca

Matthew Church, MD

Member Representing Residents

Bio | Matthew.Church@ahs.ca

Haran Yogasundaram, MD

Member Representing Residents

Bio | Haran.Yogasundaram@ahs.ca

contact

Scientific Program, Sponsorship & Registration

Contact